GSK Teams Up With EpiZyme To Develop Epigenetic Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass., biotech, a leader in epigenetics, garners its first big pharma partner.
You may also be interested in...
Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.
Eisai Deal Puts Epizyme In Position To Advance Lead Program
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.
Eisai Deal Puts Epizyme In Position To Advance Lead Program
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.